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INTRODUCTION 
Impaired glucose tolerance and impaired fasting 
glycaemia are risk factors for future development of 
diabetes and cardiovascular disease.
1
 In some age 
groups, people with diabetes have a two-fold increase in 
the risk of stroke.
2
 Diabetes is the leading cause of renal 
failure in both developed and developing countries. 
Lower limb amputations are at least 10 times more 
common in people with diabetes than in non-diabetic 
individuals in developed countries; more than half of all 
non-traumatic lower limb amputations are due to 
diabetes.
3
 It is one of the leading causes of visual 
impairment and blindness in developed countries.
4
 
People with diabetes require at least two to three times 
the health-care resources compared to people who do 
not have diabetes, and diabetes care may account for up 
to 15% of national health care budgets.
5
 In addition, the 
risk of tuberculosis is three times higher among people 
with diabetes.
6
 
Type 1 indicates the processes of beta–cell destruction 
that may ultimately lead to diabetes mellitus in which 
“insulin is required for survival” to prevent the 
development of ketoacidosis, coma and death. Type 2 is 
the most common form of diabetes and is characterized 
by disorders of insulin action and insulin secretion, 
either of which may be the predominant feature.
7
 
Diabetes is treated either by insulin or by oral anti-
diabetic drugs. Most common types of oral anti-diabetic 
drugs include sulphonylureas and biguanides.
8
 The 
sulphonylureas include gliclazide, glimepiride, 
glibenclamide, and tolbutamide. These agents stimulate 
the pancreas to produce more insulin than it otherwise 
would at a particular blood sugar level. 
METHODOLOGY 
The present study was single centered, prospective and 
observational conducted over duration of six months 
with an objective to establish safety, efficacy and 
tolerability of gliclazide against glimepiride in the 
treatment of type 2 diabetes mellitus after obtaining 
approval from the ethics committee. A total of 40 
patients who visited the outpatient block of Apollo 
hospital at Jubilee Hills, Hyderabad were enrolled in the 
study. 
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ABSTRACT: 
Background and Objective: Impaired glucose tolerance and impaired fasting glycaemia are risk categories for future 
development of diabetes and cardiovascular disease. Apart from being the leading cause of renal failure, it also increases the 
risk of lower limb amputations, visual impairment and tuberculosis. Higher incidence of Diabetes Mellitus in the last decade 
has compelled us to conduct the present study with an objective to establish safety, efficacy and tolerability of gliclazide against 
glimepiride in the treatment of type 2 Diabetes Mellitus. 
Methodology: The present study was single centered, prospective and observational conducted after obtaining approval from 
the ethics committee. A total of 40 patients who visited the outpatient block of Apollo hospital at Jubilee Hills, Hyderabad were 
enrolled in the study. A questionnaire was used to record the response of subjects participated in the study. 
Results: A higher proportion of patients belonged to the age group of 41-50 years. Gliclazide did not result in any ADR while 
glimepiride caused eight ADRs. Average reduction of FBS and PPBS in gliclazide group was found to be 52.5% and 41.3% 
respectively. Corresponding figures for glimepiride were 56.9% and 32.3%. HbA1c reduction in gliclazide and glimepiride 
group was 2.44 and 1.91 respectively. Both drugs were found to be well tolerated by the patients. 
Conclusion: Gliclazide was found to be superior in terms of safety and efficacy. Hence it can be concluded from the study that 
gliclazide is a better option in diabetes when compared to glimepiride. 
Keywords: diabetes mellitus, efficacy, gliclazide, glimepiride, safety, tolerability 
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Table 1: Drug brands of gliclazide and glimepiride used 
in the study 
Drug Name Company 
Gliclazide Diamicron Serdia 
Diamicron MR Serdia 
Glimicron Serdia 
Mylan-Gliclazide Mylan 
Glimepiride Amaryl Sanofi-Aventis 
Glimpid Ranbaxy 
Glimy Dr. Reddy's 
A questionnaire was used to record the response of 
subjects participated in the study. Drug brands that were 
used in the study are depicted in table 1. Statistical 
mean and percentages were used to analyze the 
findings. 
RESULTS 
Equal distribution of patients was done between two 
groups in the study, however variation was found 
according to gender. Majority (45%) of patients were 
from the age group of 41-50 years, while just 2.5% 
were from 71-80 years as shown in table 2. In terms of 
safety, gliclazide did not show any adverse drug 
reaction within the six months study period of treatment 
but glimepiride group evidenced few ADRs as seen in 
table 3. However, the subjects continued the treatment 
as the symptoms were not severe. Fasting blood sugar 
(FBS) and post-prandial blood sugar (PPBS) levels of 
both groups were analyzed every month during the 
study.
Table 2: Distribution of patients based on gender and age 
Age group Glimepiride Gliclazide Total 
Male Female Male Female 
21-30 2 1 - 1 4 (10.0%) 
31-40 2 1 1 2 6 (15.0%) 
41-50 3 3 4 4 14 (45.0%) 
51-60 1 4 2 3 10 (25.0%) 
61-70 1 1 1 2 5 (12.5%) 
71-80 - 1 - - 1 (2.5%) 
Total 9 (22.5%) 11 (27.5%) 8 (20.0%) 12 (30.0%) 40 (100%) 
 
Table 3: Tabular representation of Safety in both the groups i.e. Gliclazide and Glimepiride 
Drug Adverse Drug Reaction Total ADRs 
Diarrhoea Gastric Irritation Weight Gain 
Gliclazide 0 0 0 0 
Glimepiride 4 1 3 8 
 
Table 4: Tabular representation of values showing average FBS and PPBS levels (mg/dL) in gliclazide and glimepiride 
groups during six months study period 
Months Gliclazide Glimepiride 
FBS PPBS FBS PPBS 
Month 1 206.3 330.6 212.1 315.4 
Month 2 185.4 308.4 198.3 296.6 
Month 3 165.7 286.5 179.1 277.4 
Month 4 139.9 250.7 156.4 255.7 
Month 5 120.0 219.1 135.9 228.5 
Month 6 108.3 194.0 120.6 210.8 
Average reduction* 98.0 (52.5%) 136.6 (41.3%) 91.5 (56.9%) 104.6 (33.2%) 
*Average reduction is from month one to month six 
 
Average reduction of FBS and PPBS in gliclazide group 
was found to be 52.5% and 41.3% respectively. 
Corresponding figures for glimepiride were 56.9% and 
32.3% as shown in table 4. 
The data of HbA1c levels of both groups Gliclazide 
group and Glimepiride group were collected, tabulated, 
analyzed and compared during total study period of 
both groups. Table 5 shows the tri-monthly average 
HbA1C levels of gliclazide and glimepiride group 
during the total study period which shows better control 
of diabetes in gliclazide group compared to glimepiride 
group. At the end of the study, HbA1c reduction in 
gliclazide and glimepiride group was 2.44 and 1.91 
respectively.
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Table 5: HbA1c levels of both groups 
 
 
 
 
 
The data of tolerability of both groups was collected, 
tabulated and compared. It was found that both groups 
were showing well tolerance towards their respective 
drug during the study period. 
DISCUSSION 
Safety of gliclazide was better than glimepiride in the 
present study, which coincides with a previous study 
where 50% fewer hypoglycemic episodes were reported 
in gliclazide group than glimepiride users.
9
 Gliclazide 
was found to be better in terms of efficacy in the present 
study. Similar observations were reported by a study 
conducted on 870 type 2 diabetes patients of India and 
Malaysia.
10
 Both drugs were found to be well tolerated 
by the subjects during the study. 
CONCLUSION 
Gliclazide was found to be superior in terms of safety 
and efficacy. Hence it can be concluded from the study 
that gliclazide is a better option in diabetes when 
compared to glimepiride. 
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Month Gliclazide Glimepiride 
Month 1 8.82 8.71 
Month 4 6.38 6.80 
Reduction 2.44 1.91 
